Special Announcement on Investment Risks of Initial Public Offering
Sponsor (Lead Underwriter): Ping An Securities Co., Ltd.
Hunan Shengjing Shanhe Biotechnology Co., Ltd. (hereinafter referred to as "the Issuer") will publicly issue no more than 17 million RMB ordinary shares (A shares) on December 8, 2010, through the Shenzhen Stock Exchange trading system and the offline issuance electronic platform. The Issuer and the sponsor (lead underwriter) particularly remind investors to pay attention to the following:
-
Any decisions or opinions made by the China Securities Regulatory Commission and other government departments regarding this issuance do not indicate a substantive judgment or guarantee of the investment value of the Issuer's shares or the returns for investors. Any contrary statements are false representations.
-
Investors intending to participate in this issuance must carefully read the "Summary of the Prospectus for the Initial Public Offering of Hunan Shengjing Shanhe Biotechnology Co., Ltd." published on November 30, 2010, in "China Securities Journal," "Securities Times," "Shanghai Securities Journal," and "Securities Daily," as well as the full prospectus on the website (www.cninfo.com.cn), especially the sections on "Special Risk Warning" and "Risk Factors." They should fully understand the various risk factors of the Issuer, independently assess its operational status and investment value, and make prudent investment decisions. The Issuer's operational status may change due to political, economic, industry, and management factors, and any resulting investment risks should be borne by the investors.